Daptomycin
- Product NDC
- 70511-182
- Requested package NDC
- 70511-182-84
- 11-digit product format
- 705110182
- Labeler code
- 70511
- Product ID
- 70511-182_2be7556c-17a9-47ff-82bd-0b1b3316b6a1
- Type
- HUMAN PRESCRIPTION DRUG
- Nonproprietary name
- Daptomycin
- Dosage form
- INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION
- Route
- INTRAVENOUS
- Labeler
- MAIA Pharmaceuticals, Inc.
- Application
- NDA217630
- Marketing category
- NDA
- Marketing start
- 2025-09-08
- Substance
- DAPTOMYCIN
- Active strength
- 500 mg/1
- Pharmacologic classes
- Lipopeptide Antibacterial [EPC], Lipopeptides [CS]
- NDC exclude flag
- No
- Listing certified through
- 2026-12-31
- Current FDA listing
- Yes
Orange Book products#
| Application-product | Trade name | Ingredient | Strength | Dosage form / route | TE codes | RLD / RS | Approval date |
|---|---|---|---|---|---|---|---|
| N217630-001 | DAPTOMYCIN | DAPTOMYCIN | 350MG/VIAL | POWDER / INTRAVENOUS | RLD | 2024-11-21 | |
| N217630-002 | DAPTOMYCIN | DAPTOMYCIN | 500MG/VIAL | POWDER / INTRAVENOUS | RLD, RS | 2024-11-21 |
Observed Orange Book product history#
Observed FDA ZIP history: Each table is queried independently by exact application/product key from successfully parsed Orange Book snapshots. Capture times identify archived source observations; absence or a change between snapshots is not inferred. FDA publication files that were not recoverable as structured ZIP data are not represented as states.
| Captured | Edition | Application-product | Trade name | Strength | Dosage form / route | Product TE source text | RLD / RS | Approval date | Source SHA-256 |
|---|---|---|---|---|---|---|---|---|---|
| 2026-09-14 22:38:34 | 2026-08 | N217630-001 | DAPTOMYCIN | 350MG/VIAL | POWDER / INTRAVENOUS | RLD | 2024-11-21 | 84e616aacf4f… | |
| 2026-09-14 22:38:34 | 2026-08 | N217630-002 | DAPTOMYCIN | 500MG/VIAL | POWDER / INTRAVENOUS | RLD, RS | 2024-11-21 | 84e616aacf4f… | |
| 2026-08-18 06:07:40 | 2026-07 | N217630-001 | DAPTOMYCIN | 350MG/VIAL | POWDER / INTRAVENOUS | RLD | 2024-11-21 | caaa826d4ba7… | |
| 2026-08-18 06:07:40 | 2026-07 | N217630-002 | DAPTOMYCIN | 500MG/VIAL | POWDER / INTRAVENOUS | RLD, RS | 2024-11-21 | caaa826d4ba7… | |
| 2026-02-19 14:30 UTC | 2026-02 | N217630-001 | DAPTOMYCIN | 350MG/VIAL | POWDER / INTRAVENOUS | RLD | 2024-11-21 | 011fe1cb6892… | |
| 2026-02-19 14:30 UTC | 2026-02 | N217630-002 | DAPTOMYCIN | 500MG/VIAL | POWDER / INTRAVENOUS | RLD, RS | 2024-11-21 | 011fe1cb6892… | |
| 2025-12-14 10:44 UTC · 2 captures of this ZIP | 2025-12 | N217630-001 | DAPTOMYCIN | 350MG/VIAL | POWDER / INTRAVENOUS | RLD | 2024-11-21 | 31067a03dcf5… | |
| 2025-12-14 10:44 UTC · 2 captures of this ZIP | 2025-12 | N217630-002 | DAPTOMYCIN | 500MG/VIAL | POWDER / INTRAVENOUS | RLD, RS | 2024-11-21 | 31067a03dcf5… | |
| 2025-08-23 18:47 UTC | 2025-08 | N217630-001 | DAPTOMYCIN | 350MG/VIAL | POWDER / INTRAVENOUS | RLD | 2024-11-21 | 6a471c1ec25d… | |
| 2025-08-23 18:47 UTC | 2025-08 | N217630-002 | DAPTOMYCIN | 500MG/VIAL | POWDER / INTRAVENOUS | RLD, RS | 2024-11-21 | 6a471c1ec25d… | |
| 2025-03-22 03:13 UTC · 3 captures of this ZIP | 2025-03 | N217630-001 | DAPTOMYCIN | 350MG/VIAL | POWDER / INTRAVENOUS | RLD, RS | 2024-11-21 | fd3edfee7708… | |
| 2025-03-22 03:13 UTC · 3 captures of this ZIP | 2025-03 | N217630-002 | DAPTOMYCIN | 500MG/VIAL | POWDER / INTRAVENOUS | RLD, RS | 2024-11-21 | fd3edfee7708… | |
| 2025-02-26 10:13 UTC · 3 captures of this ZIP | 2025-02 | N217630-001 | DAPTOMYCIN | 350MG/VIAL | POWDER / INTRAVENOUS | RLD, RS | 2024-11-21 | b8a1b40f171c… | |
| 2025-02-26 10:13 UTC · 3 captures of this ZIP | 2025-02 | N217630-002 | DAPTOMYCIN | 500MG/VIAL | POWDER / INTRAVENOUS | RLD, RS | 2024-11-21 | b8a1b40f171c… | |
| 2025-01-19 17:59 UTC · 7 captures of this ZIP | 2025-01 | N217630-001 | DAPTOMYCIN | 350MG/VIAL | POWDER / INTRAVENOUS | RLD, RS | 2024-11-21 | 03ed91905a0d… | |
| 2025-01-19 17:59 UTC · 7 captures of this ZIP | 2025-01 | N217630-002 | DAPTOMYCIN | 500MG/VIAL | POWDER / INTRAVENOUS | RLD, RS | 2024-11-21 | 03ed91905a0d… | |
| 2024-12-13 21:23 UTC · 2 captures of this ZIP | 2024-12 | N217630-001 | DAPTOMYCIN | 350MG/VIAL | POWDER / INTRAVENOUS | RLD, RS | 2024-11-21 | 2680178bc6a6… | |
| 2024-12-13 21:23 UTC · 2 captures of this ZIP | 2024-12 | N217630-002 | DAPTOMYCIN | 500MG/VIAL | POWDER / INTRAVENOUS | RLD, RS | 2024-11-21 | 2680178bc6a6… | |
| 2026-07-26 02:55 UTC · 3 captures of this ZIP | 2026-06 | N217630-001 | DAPTOMYCIN | 350MG/VIAL | POWDER / INTRAVENOUS | RLD | 2024-11-21 | a50c72e98297… | |
| 2026-07-26 02:55 UTC · 3 captures of this ZIP | 2026-06 | N217630-002 | DAPTOMYCIN | 500MG/VIAL | POWDER / INTRAVENOUS | RLD, RS | 2024-11-21 | a50c72e98297… |
Reported adverse events (FAERS/openFDA)#
Adverse event summaries are temporarily unavailable. Other product information remains available.
Additional Listing Data#
- Finished product
- Yes
- Brand name base
- Daptomycin
- Listing expiration
- 2026-12-31
Active Ingredients#
| Ingredient | Strength |
|---|---|
| DAPTOMYCIN | 500 mg/1 |
Harmonized UNII identifiers#
| Identifier | FDA.report destination |
|---|---|
| NWQ5N31VKK | Internal UNII lookup |
Harmonized RxCUI identifiers#
Harmonized SPL set identifiers#
| Identifier | FDA.report destination |
|---|---|
| d87bd6b5-bf92-49c1-879b-dc2add3deae6 | Available on FDA.report |
DailyMed Product Concepts#
| Product concept | Relation | Version | Effective |
|---|---|---|---|
| 45ca3ac7-6ee8-4e99-92a6-dc0b401e151a | Product name | 1 | 20250724 |
| 223d8260-7a4e-4ebd-9635-845422d6a8ad | Product name | 9 | 20240909 |
| ca803a62-3799-476f-bbc6-024f77cb0320 | Product name | 4 | 20240207 |
| cad85d83-8fb9-49f8-a5a6-a399af412964 | Product name | 1 | 20230922 |
| 8e59a5ed-f224-4156-b534-1ae4d0b6dfd7 | Product name | 1 | 20230721 |
| ea2c89ab-e8f8-425f-9693-c923fa1e1703 | Product name | 1 | 20220929 |
| 1681bc73-b05f-12c3-1075-382ae39f449c | Product name | 1 | 20140508 |
DailyMed Package Descriptions#
| Package NDC | Product | Description | Form | Quantity | Strength | SPL version |
|---|---|---|---|---|---|---|
| 70511-182-15 | Daptomycin | 1 in 1 VIAL, SINGLE-DOSE | INJECTION, POWDER, LYOPHILIZED, | 1 | 3 | |
| 70511-182-84 | Daptomycin | 10 in 1 CARTON | INJECTION, POWDER, LYOPHILIZED, | 10 | 3 |
DailyMed Dashboard NDC Coverage#
openFDA label cross-check#
OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.
| Brand | Generic | Manufacturer | SPL set ID | Effective date | Available safety fields | Join |
|---|---|---|---|---|---|---|
| Daptomycin | DAPTOMYCIN | Par Health USA, LLC | c1d47001-5e0f-46a3-b220-53f46b4fd6ac | 2025-08-19 | Warnings, Adverse reactions | 217630 NDA217630 |
| Daptomycin | DAPTOMYCIN | MAIA Pharmaceuticals, Inc. | d87bd6b5-bf92-49c1-879b-dc2add3deae6 | 2025-07-16 | Warnings, Adverse reactions | 217630 NDA217630 70511-182-84 70511-182 70511018284 |
DailyMed RxNorm Mappings#
| RxCUI | RxNorm string | TTY | DailyMed | SPL version |
|---|---|---|---|---|
| 1996246 | DAPTOmycin 350 MG Injection | PSN | d87bd6b5-bf92-49c1-879b-dc2add3deae6 | 3 |
| 403920 | DAPTOmycin 500 MG Injection | PSN | d87bd6b5-bf92-49c1-879b-dc2add3deae6 | 3 |
| 1996246 | daptomycin 350 MG Injection | SCD | d87bd6b5-bf92-49c1-879b-dc2add3deae6 | 3 |
| 403920 | daptomycin 500 MG Injection | SCD | d87bd6b5-bf92-49c1-879b-dc2add3deae6 | 3 |
Packages#
| Package NDC | 11-digit format | Description | Marketing start | Sample | Exclude flag | Status |
|---|---|---|---|---|---|---|
| 70511-182-84 | 70511018284 | 10 VIAL, SINGLE-DOSE in 1 CARTON (70511-182-84) / 1 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION in 1 VIAL, SINGLE-DOSE (70511-182-15) | 2025-09-08 | No | No | Current |